- Home
- TOI vs RCKT Comparison
TOI vs RCKT Comparison
Compare TOI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOI
- RCKT
- Stock Information
- Founded
- TOI 2007
- RCKT 1999
- Country
- TOI United States
- RCKT United States
- Employees
- TOI N/A
- RCKT N/A
- Industry
- TOI Medical/Nursing Services
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- TOI Health Care
- RCKT Health Care
- Exchange
- TOI Nasdaq
- RCKT Nasdaq
- Market Cap
- TOI 393.4M
- RCKT 328.6M
- IPO Year
- TOI N/A
- RCKT N/A
- Fundamental
- Price
- TOI $3.76
- RCKT $3.05
- Analyst Decision
- TOI Strong Buy
- RCKT Buy
- Analyst Count
- TOI 1
- RCKT 13
- Target Price
- TOI $6.00
- RCKT $12.88
- AVG Volume (30 Days)
- TOI 1.9M
- RCKT 2.5M
- Earning Date
- TOI 08-13-2025
- RCKT 08-07-2025
- Dividend Yield
- TOI N/A
- RCKT N/A
- EPS Growth
- TOI N/A
- RCKT N/A
- EPS
- TOI N/A
- RCKT N/A
- Revenue
- TOI $424,376,000.00
- RCKT N/A
- Revenue This Year
- TOI $19.40
- RCKT N/A
- Revenue Next Year
- TOI N/A
- RCKT $591.46
- P/E Ratio
- TOI N/A
- RCKT N/A
- Revenue Growth
- TOI 17.53
- RCKT N/A
- 52 Week Low
- TOI $0.13
- RCKT $2.19
- 52 Week High
- TOI $4.50
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- TOI 53.14
- RCKT 49.19
- Support Level
- TOI $3.50
- RCKT $2.83
- Resistance Level
- TOI $4.50
- RCKT $3.22
- Average True Range (ATR)
- TOI 0.32
- RCKT 0.17
- MACD
- TOI -0.06
- RCKT 0.01
- Stochastic Oscillator
- TOI 35.65
- RCKT 41.51
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.